Selective criteria for plasma samples obtained from participants and participants’ background clinical characteristics; discriminatory performance between pancreatic cancer and healthy controls as the primary end point; distribution of plasma apoA2-i concentration and discriminatory performance for stage I pancreatic cancer and pancreatic cancer < 2 cm. Here, APOA2 is linked to pancreatic neoplasm.